百时美施贵宝Bristol Myers Squibb Co. (BMY) 2015年年度报告「NYSE」.pdf

1、5asdBrenda Cushing,diagnosed with non-small cell lung cancer,is now being treated with an Immuno-Oncology therapy from Bristol-Myers Squibb.WORKING TOGETHER FOR PATIENTS2015|Annual Report345 Park Avenue New York,NY 10154-0037 212-546-4000 Follow us on:bmsnews Bristol-Myers Squibb 13/8/16 11:34 AMThe

2、 patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses.In addition,there is no guarantee that potential drugs or indications still in development will receive regulatory appro

3、val.BRENDA CUSHINGGoing the Extra Mile Brenda and Ed Cushing were on their Harley-Davidson motorcycles,enjoying the New England countryside.“Suddenly I had a sharp pain in my right shoulder and I became short of breath,”Brenda says.“I knew it wasnt normal.”Her doctor diagnosed pneumonia and sent her

4、 home with antibiotics.But her symptoms persisted.Finally,scans revealed a mass in her lungs.Brenda was diagnosed with non-small cell lung cancer(NSCLC)with metastases in her ribs and brain.“Suddenly,my life came crashing down.”NSCLC is the most prevalent form of lung cancer,resulting in nearly 150,

5、000 deaths annually in the U.S.On chemotherapy,Brenda felt exhausted,depressed and sick.Her hair fell out in clumps.After five rounds of chemo,the tumors had doubled in size.“I told my oncologist that I was done with treatment.”Joe Clossick(above on the right),a Bristol-Myers Squibb oncology sales r

6、epresentative,got a phone call.“My friend Brian said someone who works for him had lung cancer and was in a bad place.”It was Brenda.Joe suggested that she talk to her doctor about Opdivo(nivolumab),a cancer Immuno-Oncology treatment.First approved in December 2014,Opdivo is now approved in the U.S.